Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesOctober 14, 2009New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met (pioglitazone HCl and metformin HCl) as Initial Therapy Compared to Either Component Alone
Takeda Pharmaceuticals North America, 10/16/09
A study, published online in the journal Current Medical Research and Opinion, showed that a greater percentage of patients with type 2 diabetes treated with the fixed–dose combination ACTOplus met as initial therapy reached the study goal of hemoglobin A1c (HbA1c) of <7 percent compared to either component alone. Safety and tolerability of ACTOplus met therapy were evaluated by rate of drug discontinuation and treatment–emergent adverse events.
Today in Major Studies...keeping you current
Receive free subspecialty "5-minute updates" via email
Carboplatin-Pemetrexed Adjuvant Chemotherapy in Resected Non-small Cell Lung Cancer (NSCLC): A Phase II Study
Anticancer Research, 11/16/09
A simple cost-effective high performance liquid chromatographic assay of sulphadoxine in whole blood spotted on filter paper for field studies
Malaria Journal, 10/27/09
Psychopharmacology Curriculum Field Test
Academic Psychiatry, 10/16/09
Sponsor
Article Search
Sponsor